( for activity in rheumatoid arthritis ...)Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis,Health

for
activity in rheumatoid arthritis - and it is this region that has often been associated with cellular cytotoxicity," commented Professor Edward Keystone, Professor of Medicine, University of Toronto, Canada. "The consistency of the RAPID data confirm that
certolizumab pegol may provide a valuable new treatment option for patients with this condition."

The safety and tolerability profile of CIMZIA(TM) in both RAPID studies was consistent with that expected of an anti-TNF agent.

In another study presented at the meeting, the 011 trial, the efficacy of CIMZIA(TM) 400 mg every four weeks as monotherapy was compared with that of placebo in treating the signs and symptoms of RA in patients who had previously failed on one or more courses of a
DMARD. The primary endpoint, ACR20 response at 24 weeks, was significantly higher in the CIMZIA(TM) treated arm than in the
placebo treated arm (45.5% vs 9.3%: p<0.001). ACR50 and ACR70 responses were also both achieved with statistical significance.
CIMZIA(TM) was also significantly superior to placebo in terms of median time to first ACR20 response (2.0 vs 19.9 weeks, p<0.001),
with 80.6% of ACR20 responders having achieved response by week 1.

"These data show the potential of certolizumab pegol to safely and effectively treat patients who have previously failed disease
modifying antirheumatic drug treatments," added Prof. Josef Smolen, Chairman of the Department of Rheumatology, Medical University of
Vienna, Austria. "In addition, certolizumab pegol could provide a valuable option in patients who are unable to take or cannot tolerate
methotrexate."

Preparation for a regulatory submission for CIMZIA(TM) in the treatment of RA is ongoing, with filing planned by the end of 2007.

Enquiries please contact:

+---------------------------------------------------------------------------------------------+
|Investor Relations
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Gabapentin Shown Effective for Fibromyalgia Pain
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
6. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
7. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
8. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
9. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
10. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
11. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression